Home › Research › Caregiving
Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD
Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S.. Neurology, 2005-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Abeta42-immunization reduces plaque burden and improves cognition in transgenic mouse models of Alzheimer disease (AD). This phase 1 study evaluated the safety, tolerability, and immunogenicity of AN1792 (human aggregated Abeta42) in patients with mild to moderate AD. Methods Twenty patients were enrolled into each of four dose groups and randomly assigned to receive IM AN1792 (50 or 225 microg) with QS-21 adjuvant (50 or 100 microg) or QS-21 only (control) in a 4:1 active:control ratio on day 0 and at weeks 4, 12, and 24. Patients could receive up to four additional injections of a polysorbate 80 modified formulation at weeks 36, 48, 60, and 72. Safety, tolerability, immunogenicity, and exploratory evidence of efficacy were evaluated. Results Treatment-related adverse events were reported in 19 (23.8%) patients, but no relationship was observed between AN1792 dose and incidence. One patient developed meningoencephalitis that was diagnosed after death (not directly related to study treatment) and 219 days after discontinuing from the study. Five deaths occurred during the study follow-up, but none was considered to be directly related to study treatment. During the period of the first four injections, 23.4% of AN1792-treated patients had a positive anti-AN1792 antibody titer (an anti-AN1792 antibody titer of > or =1:1,000). This increased to 58.8% after additional injections with the modified formulation. Disability Assessment for Dementia scores showed less decline among active compared with control patients at week 84 (p = 0.002). No treatment differences were observed in three other efficacy measures. Conclusions AN1792 + QS-21 elicited a positive antibody response to Abeta42 in more than half of this elderly study population.
What this study adds
Evidence grade: Low
This is a trial. In this phase 1 study, AN1792 produced an antibody response in some patients and Disability Assessment for Dementia scores showed less decline among treated patients than controls at week 84. Reported effect size: 23.8%; 23.4%; 58.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., et al. (2005). Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. https://doi.org/10.1212/01.wnl.0000148604.77591.67
Vancouver
Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005. doi:10.1212/01.wnl.0000148604.77591.67. PMID: 15642910.
BibTeX
@article{bayer2005-15642910,
author = {Bayer, A. J. and Bullock, R. and Jones, R. W. and Wilkinson, D. and Paterson, K. R. and Jenkins, L. and Millais, S. B. and Donoghue, S.},
title = {{Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD}},
journal = {Neurology},
year = {2005},
doi = {10.1212/01.wnl.0000148604.77591.67},
pmid = {15642910},
url = {https://doi.org/10.1212/01.wnl.0000148604.77591.67}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results Treatment-related adverse events were reported in 19 (23.8%) patients, but no relationship was observed between AN1792 dose and incidence.
- Disability Assessment for Dementia scores showed less decline among active compared with control patients at week 84 (p = 0.002).
Why it matters
In this phase 1 study, AN1792 produced an antibody response in some patients and Disability Assessment for Dementia scores showed less decline among treated patients than controls at week 84. Treatment-related adverse events occurred in some patients, and one patient developed meningoencephalitis diagnosed after death.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Study designclinical trial
- Effect size23.8%; 23.4%; 58.8%
- Evidence strengthLow
How this study scored 54/100
Published in a leading specialty journal. Scored zero for study design and sample size because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2005 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 6 / 7 | Cited 356 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.5 citations a year over 23 year(s) since 2005 |
| Impact for its field and year | 4 / 6 | Cited 15.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 15 other studies in this library |
| Still being cited | 2 / 4 | Cited 26 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Stephen Donoghue: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University of Wales: institution h-index 571 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 15642910) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/01.wnl.0000148604.77591.67
- PubMed: 15642910
- Original source →
- Free full text: UWE Research Repository (UWE Bristol) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
15 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Caregiving from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.